Prevnar

Prevnar
Name	Prevnar
Caption	Conjugate pneumococcal vaccine
Type	Vaccine
Target	Streptococcus pneumoniae
Tradename	Prevnar
Developer	Pfizer
Introduced	2000

Prevnar is a conjugate pneumococcal vaccine used to prevent invasive disease and otitis media caused by Streptococcus pneumoniae. It is produced by Pfizer and has been recommended in national immunization programs by agencies such as the Centers for Disease Control and Prevention, the World Health Organization, and the European Medicines Agency. The vaccine has influenced public health policy in countries including the United States, the United Kingdom, and Australia through reductions in pneumonia, bacteremia, and meningitis incidence.

Medical uses

Prevnar is indicated for prevention of invasive pneumococcal disease, pneumonia, and acute otitis media in pediatric and adult populations targeted by agencies such as the Advisory Committee on Immunization Practices, the National Institute for Health and Care Excellence, and the Joint Committee on Vaccination and Immunisation. It is used in routine childhood schedules endorsed by ministries of health in Canada, Germany, and Japan, and in catch-up campaigns run by organizations such as Gavi, the Vaccine Alliance and the Pan American Health Organization. Clinical guidance from bodies including the American Academy of Pediatrics, the Royal College of Paediatrics and Child Health, and the Infectious Diseases Society of America informs use in immunocompromised patients, elderly cohorts, and people with chronic conditions managed by institutions such as Mayo Clinic, Cleveland Clinic, and Johns Hopkins Hospital.

Composition and formulation

Prevnar is a protein–polysaccharide conjugate vaccine that pairs capsular polysaccharides from multiple pneumococcal serotypes to carrier proteins; formulations reference serotypes characterized by researchers at institutions like the Centers for Disease Control and Prevention and the Statens Serum Institut. The formulation process builds on conjugation chemistry used in vaccines such as the Haemophilus influenzae type b vaccine and techniques refined at companies including Wyeth and GlaxoSmithKline. Different versions contain varying numbers of serotypes — formulations influenced by serotype epidemiology reported by the European Centre for Disease Prevention and Control, the National Institutes of Health, and surveillance networks like the Global Pneumococcal Sequencing Project. Manufacturing quality control employs methods established by regulatory labs such as the Food and Drug Administration and the Paul Ehrlich Institute.

Efficacy and clinical trials

Efficacy was established through randomized controlled trials and surveillance studies led by investigators associated with universities such as Harvard University, University of Oxford, and Stanford University and published in journals like The New England Journal of Medicine, The Lancet, and JAMA. Trials demonstrated reductions in invasive pneumococcal disease and vaccine-type carriage, with herd immunity effects documented in population studies coordinated by agencies including the Centers for Disease Control and Prevention and the Public Health Agency of Canada. Comparative effectiveness against all-cause pneumonia and otitis media has been assessed in multi-center studies sponsored by pharmaceutical companies such as Pfizer and academic consortia involving the Bill & Melinda Gates Foundation and the Wellcome Trust.

Safety and adverse effects

Safety profiles were evaluated in pre-licensure studies monitored by regulators including the Food and Drug Administration, the European Medicines Agency, and national pharmacovigilance centers like the Yellow Card Scheme. Common local and systemic reactions were reported in clinical trials coordinated by hospitals such as Boston Children's Hospital and Great Ormond Street Hospital, while post-marketing surveillance identified rare events assessed by specialist groups at institutions such as the Vaccine Adverse Event Reporting System and the European Medicines Agency. Risk–benefit assessments by advisory committees including the Advisory Committee on Immunization Practices and the National Vaccine Advisory Committee guide safety recommendations and contraindications used by providers at clinics like Kaiser Permanente and Mount Sinai Health System.

Immunization schedules and recommendations

Immunization schedules vary by country and are issued by authorities such as the Centers for Disease Control and Prevention, the World Health Organization, and the European Medicines Agency, with pediatric schedules aligned with guidance from the American Academy of Pediatrics and the Royal College of Paediatrics and Child Health. Typical childhood schedules integrate doses at ages determined by national programs in the United States, United Kingdom, and Australia and by pediatric societies in India and Brazil. Recommendations for adults, including older adults and those with chronic diseases, are shaped by professional organizations such as the Infectious Diseases Society of America and the American College of Physicians and implemented through primary care networks like the National Health Service and managed-care organizations such as Humana.

History and approval

Development involved academic and industry collaborations between researchers at universities such as Yale University and Columbia University and pharmaceutical firms including Wyeth and later Pfizer. Initial licensure in 2000 followed submissions to regulators including the Food and Drug Administration and subsequent approvals by the European Medicines Agency and national agencies in Australia and Canada. The rollout was accompanied by policy decisions from bodies such as the Advisory Committee on Immunization Practices, public health campaigns by ministries in South Africa and Mexico, and procurement negotiations conducted with organizations like Gavi, the Vaccine Alliance.

Manufacturing and distribution

Manufacturing operations are managed by Pfizer with quality oversight consistent with standards from agencies such as the Food and Drug Administration, the European Medicines Agency, and the World Health Organization's prequalification program. Distribution utilizes global supply chains coordinated with partners including national immunization programs in Nigeria, Pakistan, and Indonesia and procurement agencies such as the Pan American Health Organization and UNICEF for vaccine delivery to clinics like Red Cross-supported centers and hospital networks including AIIMS and Charité – Universitätsmedizin Berlin. Cold-chain logistics follow guidelines from organizations such as the World Health Organization, with post-marketing surveillance data collected by regional centers like the Africa Centres for Disease Control and Prevention.

Category:Pneumococcal vaccines